Cutaneous reaction to BNT162b2 mRNA COVID‐19 vaccine

Real‐time reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 detection from nasopharyngeal exudate was negative. Both are lipid‐nanoparticle‐encapsulated RNA encoding SARS‐CoV‐2 spike protein and are administered by injection into the deltoid muscle in a two‐dose regimen.2,...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Dermatology 2021-07, Vol.60 (7), p.891-892
Main Authors: López‐Valle, Alba, Falkenhain‐López, Daniel, Arranz, Celia R.
Format: Article
Language:English
Subjects:
BNT162 Vaccine
Correspondence
COVID-19
COVID-19 Vaccines
Humans
mRNA
RNA, Messenger
SARS-CoV-2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Real‐time reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 detection from nasopharyngeal exudate was negative. Both are lipid‐nanoparticle‐encapsulated RNA encoding SARS‐CoV‐2 spike protein and are administered by injection into the deltoid muscle in a two‐dose regimen.2, 3 In the clinical trial of BNT162b2 vaccine,2 the percentage of local reactions in patients between 16 and 55 years, 1–7 days after the first dose, was: 78% pain, 6% redness, and 6% inflammation. Compared to the clinical trial of the mRNA‐1273 vaccine,3 and to a phase I trial of another lipid‐nanoparticle‐mRNA vaccine,4 local and systemic reactions were similar among all mRNA and conventional vaccines.
ISSN:0011-9059
1365-4632
DOI:10.1111/ijd.15575